Our Advantages
Hangzhou Jinlan Pharm-Drugs Technology Co. Ltd.(JL Pharm) is an advanced pharmaceutical corporation with a laboratory of 1200 square meters in Nanjing city, and cooperative GMP production plants in Beljing, Jiangsu, Zhejiang, Jiangxi, Chengdrand Shandong.We can provide both CDMO technology research and development services, and a ful range of laboratory R&D and production services for raw materials and pharmaceutical intermediates to globapharmaceutical companies during which synthetic route research and development, process reearch and development and optimization, scale-up production, domestic and foreign drug registration, and industrial equipment selection, automatic control system and technical process packages.
Product Description
| Product Name: |
Relugolix |
| Synonyms: |
TAK-385;Relugolix;Altropane;TKA-385 Relugolix;1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-6-thieno[4,5-e]pyrimidinyl]phenyl]-3-methoxyurea;Relugolix TAK-385;TAK-385,Relugolix;CS-2851 |
| CAS: |
737789-87-6 |
| MF: |
C29H27F2N7O5S |
| MW: |
623.63 |
| EINECS: |
|
| Product Categories: |
API;737789-87-6 |
| Mol File: |
737789-87-6.mol |
|
| |
Installation Instructions
| Melting point |
228 °C (decomp)(Solv: ethyl acetat tetrahydrofura |
| density |
1.442±0.06 g/cm3(Predicted) |
| storage temp. |
Store at -20°C |
| solubility |
DMSO:20.0(Max Conc. mg/mL);32.1(Max Conc. mM)
Ethanol:1.0(Max Conc. mg/mL);1.6(Max Conc. mM) |
| form |
A crystalline solid |
| pka |
13.17±0.70(Predicted) |
| InChIKey |
AOMXMOCNKJTRQP-UHFFFAOYSA-N |
| SMILES |
N(C1=CC=C(C2SC3=C(C=2CN(C)C)C(=O)N(C2=NN=C(OC)C=C2)C(=O)N3CC2=C(F)C=CC=C2F)C=C1)C(NOC)=O |
| Uses |
Relugolix is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment |
| Mechanism of action |
The mechanism of action of relugolix is as a Gonadotropi Releasing Hormone Receptor Antagonist, and Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer, and Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor. The physiologic effect of relugolix is by means of Decreased GnRH Secretion. |
| Synthesis |
Relugolix is produced by the reaction of 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione and phenyl N-methoxycarbamate. |
Audited Supplier 
){kind=link}
){kind=link}